Clinical Trial

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Study acronym: BLISSc-ILD
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2023-05-19; most recent amendment 2026-01-09.
Status change: Not Yet Recruiting → Recruiting 2023-11-16
Trial Details
NCT Number NCT05878717
Lead Sponsor GlaxoSmithKline
Conditions Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Enrollment 300 participants
Start Date 2023-09-13
Primary Completion 2029-05-17 (estimated)
Study Completion 2029-07-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-12